Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Collins Helen Louise, holds the title of Director at Kura Oncology, Inc..
On 2026-06-04, the insider transacted 35,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
**Transaction:** grant of 35,000 shares by Collins Helen Louise (Director). **Strategic Implications (Investor Edge):** This grant is routine compensation for a director and carries no actionable signal about the company's prospects or insider conviction. Investors should not interpret this as bullish or bearish. **Key Takeaways:** - The transaction is a grant, not an open market purchase, so it lacks the conviction signal of a discretionary buy. - The insider is a director, not a C-suite executive, reducing the significance of the trade. - No price or value was reported, typical for grants, making it impossible to assess the insider's valuation view.
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.